Metabolomics - A wide-open door to personalized treatment in chronic heart failure?
Heart failure (HF) is a complex syndrome representing a final stage of various cardiovascular diseases. Despite significant improvement in the diagnosis and treatment (e.g. ACE-inhibitors, β-blockers, aldosterone antagonists, cardiac resynchronization therapy) of the disease, prognosis of optimally treated patients remains very serious and HF mortality is still unacceptably high. Therefore there is a strong need for further exploration of novel analytical methods, predictive and prognostic biomarkers and more personalized treatment. The metabolism of the failing heart being significantly impaired from its baseline state may be a future target not only for biomarker discovery but also for the pharmacologic intervention. However, an assessment of a particular, isolated metabolite or protein cannot be fully informative and makes a correct interpretation difficult. On the other hand, metabolites profile analysis may greatly assist investigator in an interpretation of the altered pathway dynamics, especially when combined with other lines of evidence (e.g. metabolites from the same pathway, transcriptomics, proteomics). Despite many prior studies on metabolism, the knowledge of peripheral and cardiac pathophysiological mechanisms responsible for the metabolic imbalance and progression of the disease is still insufficient. Metabolomics enabling comprehensive characterization of low molecular weight metabolites (e.g. lipids, sugars, organic acids, amino acids) that reflects the complete metabolic phenotype seems to be the key for further potential improvement in HF treatment (diet-based or biochemical-based). Will this -omics technique one day open a door to easy patients identification before they have a heart failure onset or its decompensation?
Cardiology Department, University Hospital, Bialystok, Poland.
M
M
Marcinkiewicz-Siemion
Clinical Research Centre, Medical University of Bialystok, Poland.
M
M
Ciborowski
Clinical Research Centre, Medical University of Bialystok, Poland.
A
A
Kretowski
Cardiology Department, University Hospital, Bialystok, Poland.
W J
WJ
Musial
Cardiology Department, University Hospital, Bialystok, Poland; Department of Population Medicine and Civilization Disease Prevention, Medical University of Bialystok, Poland. Electronic address: fizklin@wp.pl.
K A
KA
Kaminski
D002908:Chronic Disease; D006333:Heart Failure / Q000235:genetics / Q000378:metabolism* / Q000628:therapy*; D006801:Humans; D055432:Metabolomics / Q000379:methods* / Q000639:trends; D057285:Precision Medicine / Q000379:methods* / Q000639:trends; D040901:Proteomics / Q000379:methods / Q000639:trends; D016896:Treatment Outcome
Cardiac metabolism; Heart failure; High throughput techniques; Metabolic pathways; Metabolites; Metabolomics